cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Uniqure Nv
6 own
12 watching
Current Price
$21.39
$-0.21
(-0.97%)
logo-qure
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
998.58M
52-Week High
52-Week High
28.255
52-Week Low
52-Week Low
12.52
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
5.0703
iconMarket Capitalization998.58M
icon52-Week High28.255
icon52-Week Low12.52
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio5.0703
What does the Uniqure Nv do?
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More
How much money does Uniqure Nv make?
News & Events about Uniqure Nv.
Globe Newswire
1month ago
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients ...
PR Newswire
1month ago
CSL's Novel Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment CSL's Novel Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates Durable...
Globe Newswire
1month ago
~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...
Globe Newswire
6 months ago
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-...
PR Newswire
10 months ago
European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B PR Newswire MARBURG, Germany, March 28...
Frequently Asked Questions
Frequently Asked Questions
What is Uniqure Nv share price today?
plus_minus_icon
Can Indians buy Uniqure Nv shares?
plus_minus_icon
How can I buy Uniqure Nv shares from India?
plus_minus_icon
Can Fractional shares of Uniqure Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Uniqure Nv stocks?
plus_minus_icon
What is today’s traded volume of Uniqure Nv?
plus_minus_icon
What is today’s market capitalisation of Uniqure Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Uniqure Nv?
plus_minus_icon
What percentage is Uniqure Nv down from its 52-Week High?
plus_minus_icon
What percentage is Uniqure Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$21.39
$-0.21
(-0.97%)
logo-qure
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.93
$0.06 (2.09 %)
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$28.47
$-0.11 (-0.38 %)
Ardelyx Inc
Ardelyx Inc
$2.93
$-0.27 (-8.44 %)
Veracyte, Inc.
Veracyte, Inc.
$26.06
$0.31 (1.20 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.93
$0.06 (2.09 %)
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$28.47
$-0.11 (-0.38 %)
Ardelyx Inc
Ardelyx Inc
$2.93
$-0.27 (-8.44 %)
Veracyte, Inc.
Veracyte, Inc.
$26.06
$0.31 (1.20 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00